| Year |
Citation |
Score |
| 2022 |
Musacchio T, Yin J, Kremer F, Koprich JB, Brotchie JM, Volkmann J, Ip CW. Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T α-synuclein rat model of Parkinson's disease. Behavioural Brain Research. 432: 113968. PMID 35738338 DOI: 10.1016/j.bbr.2022.113968 |
0.317 |
|
| 2022 |
Hauser RA, Giladi N, Poewe W, Brotchie J, Friedman H, Oren S, Litman P. P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease. Advances in Therapy. 39: 1881-1894. PMID 35267155 DOI: 10.1007/s12325-022-02097-2 |
0.349 |
|
| 2020 |
Schneider JS, Marshall CA, Keibel L, Snyder NW, Hill MP, Brotchie JM, Johnston TH, Waterhouse BD, Kortagere S. A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease. Experimental Neurology. 335: 113514. PMID 33141071 DOI: 10.1016/j.expneurol.2020.113514 |
0.303 |
|
| 2020 |
Depoortere R, Johnston TH, Fox SH, Brotchie JM, Newman-Tancredi A. The selective 5-HT receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques. Parkinsonism & Related Disorders. 78: 151-157. PMID 32846366 DOI: 10.1016/j.parkreldis.2020.08.009 |
0.459 |
|
| 2020 |
Titze-de-Almeida SS, Soto-Sánchez C, Fernandez E, Koprich JB, Brotchie JM, Titze-de-Almeida R. The Promise and Challenges of Developing miRNA-Based Therapeutics for Parkinson's Disease. Cells. 9. PMID 32244357 DOI: 10.3390/cells9040841 |
0.357 |
|
| 2020 |
McKinnon C, De Snoo ML, Gondard E, Neudorfer C, Chau H, Ngana SG, O'Hara DM, Brotchie JM, Koprich JB, Lozano AM, Kalia LV, Kalia SK. Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein. Acta Neuropathologica Communications. 8: 17. PMID 32059750 DOI: 10.1186/s40478-020-0894-0 |
0.339 |
|
| 2020 |
Barth AL, Schneider JS, Johnston TH, Hill MP, Brotchie JM, Moskal JR, Cearley CN. NYX-458 improves cognitive performance in a primate Parkinson's disease model. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 31967361 DOI: 10.1002/Mds.27962 |
0.403 |
|
| 2019 |
Schneider JS, Aras R, Williams CK, Koprich JB, Brotchie JM, Singh V. GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease. Scientific Reports. 9: 8362. PMID 31182727 DOI: 10.1038/s41598-019-42847-x |
0.444 |
|
| 2019 |
Howson PA, Johnston TH, Ravenscroft P, Hill MP, Su J, Brotchie JM, Koprich JB. Beneficial effects of trehalose on striatal dopaminergic deficits in rodent and primate models of synucleinopathy in Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. PMID 30918068 DOI: 10.1124/jpet.118.255695 |
0.444 |
|
| 2018 |
Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30575996 DOI: 10.1002/Mds.27565 |
0.405 |
|
| 2018 |
Fox SH, Brotchie JM. Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold? The European Journal of Neuroscience. PMID 30269407 DOI: 10.1111/ejn.14173 |
0.308 |
|
| 2018 |
Brigham E, Johnston T, Brown C, Holt J, Fox S, Hill M, Howson P, Brotchie J, Nguyen J. Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia. The Journal of Pharmacology and Experimental Therapeutics. PMID 30087157 DOI: 10.1124/jpet.118.247650 |
0.379 |
|
| 2018 |
Johnston TH, Lacoste AMB, Visanji NP, Lang AE, Fox SH, Brotchie JM. Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease. Neuropharmacology. PMID 29907424 DOI: 10.1016/j.neuropharm.2018.05.035 |
0.345 |
|
| 2018 |
Henrich MT, Geibl FF, Lee B, Chiu WH, Koprich JB, Brotchie JM, Timmermann L, Decher N, Matschke LA, Oertel WH. A53T-α-synuclein overexpression in murine locus coeruleus induces Parkinson's disease-like pathology in neurons and glia. Acta Neuropathologica Communications. 6: 39. PMID 29747690 DOI: 10.1186/S40478-018-0541-1 |
0.378 |
|
| 2018 |
Gleave JA, Arathoon LR, Trinh D, Lizal KE, Giguère N, Barber JEM, Najarali Z, Hassan Khan M, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE. Corrigendum to "Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism" [Neurobiol. Dis. 106 (2018) 133-146]. Neurobiology of Disease. PMID 29571591 DOI: 10.1016/J.Nbd.2018.02.018 |
0.308 |
|
| 2017 |
Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease. Neuropharmacology. PMID 29197517 DOI: 10.1016/j.neuropharm.2017.11.046 |
0.515 |
|
| 2017 |
Koprich JB, Brotchie JM, Musacchio T, Volkmann J, Ip CW. Reply to Can STN DBS protect both nigral somata and innervation of the striatum? Annals of Neurology. PMID 28985651 DOI: 10.1002/Ana.25066 |
0.326 |
|
| 2017 |
Koprich JB, Kalia LV, Brotchie JM. Animal models of α-synucleinopathy for Parkinson disease drug development. Nature Reviews. Neuroscience. PMID 28747776 DOI: 10.1038/nrn.2017.75 |
0.346 |
|
| 2017 |
Arathoon LR, Gleave JA, Trinh D, Lizal KE, Giguère N, Barber JHM, Najarali Z, Hassan Khan M, Thiele SL, Semmen MS, Koprich JB, Brotchie JM, Eubanks JH, Trudeau LE, Nash JE. Sirtuin 3 rescues neurons through the stabilisation of mitochondrial biogenetics in the virally-expressing mutant α-synuclein rat model of parkinsonism. Neurobiology of Disease. PMID 28673739 DOI: 10.1016/J.Nbd.2017.06.009 |
0.415 |
|
| 2017 |
Musacchio T, Rebenstorff M, Fluri F, Brotchie JM, Volkmann J, Koprich JB, Ip CW. STN-DBS is neuroprotective in the A53T α-synuclein Parkinson's disease rat model. Annals of Neurology. PMID 28470693 DOI: 10.1002/Ana.24947 |
0.433 |
|
| 2017 |
Ip CW, Klaus LC, Karikari AA, Visanji NP, Brotchie JM, Lang AE, Volkmann J, Koprich JB. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Acta Neuropathologica Communications. 5: 11. PMID 28143577 DOI: 10.1186/S40478-017-0416-X |
0.401 |
|
| 2016 |
Koprich JB, Johnston TH, Reyes G, Omana V, Brotchie JM. Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinson's Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque. Plos One. 11: e0167235. PMID 27902767 DOI: 10.1371/journal.pone.0167235 |
0.394 |
|
| 2016 |
Visanji NP, Brotchie JM, Kalia LV, Koprich JB, Tandon A, Watts JC, Lang AE. α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era. Trends in Neurosciences. PMID 27776749 DOI: 10.1016/J.Tins.2016.09.003 |
0.382 |
|
| 2016 |
Ip CW, Isaias IU, Kusche-Tekin BB, Klein D, Groh J, O'Leary A, Knorr S, Higuchi T, Koprich JB, Brotchie JM, Toyka KV, Reif A, Volkmann J. Tor1a+/- mice develop dystonia-like movements via a striatal dopaminergic dysregulation triggered by peripheral nerve injury. Acta Neuropathologica Communications. 4: 108. PMID 27716431 DOI: 10.1186/S40478-016-0375-7 |
0.374 |
|
| 2016 |
Huot P, Fox SH, Brotchie JM. Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of Nonhuman Primate Studies and Clinical Trials. The Journal of Pharmacology and Experimental Therapeutics. 357: 562-9. PMID 27190169 DOI: 10.1124/Jpet.116.232371 |
0.473 |
|
| 2015 |
Huot P, Johnston TH, Fox SH, Newman-Tancredi A, Brotchie JM. The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque. Neuropharmacology. 97: 306-11. PMID 26071982 DOI: 10.1016/J.Neuropharm.2015.05.033 |
0.424 |
|
| 2015 |
He Q, Koprich JB, Wang Y, Yu WB, Xiao BG, Brotchie JM, Wang J. Treatment with Trehalose Prevents Behavioral and Neurochemical Deficits Produced in an AAV α-Synuclein Rat Model of Parkinson's Disease. Molecular Neurobiology. PMID 25972237 DOI: 10.1007/s12035-015-9173-7 |
0.417 |
|
| 2015 |
Huot P, Fox SH, Brotchie JM. Monoamine reuptake inhibitors in Parkinson's disease. Parkinson's Disease. 2015: 609428. PMID 25810948 DOI: 10.1155/2015/609428 |
0.443 |
|
| 2015 |
Phookan S, Sutton AC, Walling I, Smith A, O'Connor KA, Campbell JC, Calos M, Yu W, Pilitsis JG, Brotchie JM, Shin DS. Gap junction blockers attenuate beta oscillations and improve forelimb function in hemiparkinsonian rats. Experimental Neurology. 265: 160-70. PMID 25622779 DOI: 10.1016/J.Expneurol.2015.01.004 |
0.337 |
|
| 2015 |
Samuel M, Rodriguez-Oroz M, Antonini A, Brotchie JM, Ray Chaudhuri K, Brown RG, Galpern WR, Nirenberg MJ, Okun MS, Lang AE. Management of impulse control disorders in Parkinson's disease: Controversies and future approaches. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 150-9. PMID 25607799 DOI: 10.1002/Mds.26099 |
0.36 |
|
| 2015 |
Huot P, Johnston TH, Fox SH, Brotchie JM. Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study. Synapse (New York, N.Y.). 69: 99-102. PMID 25559284 DOI: 10.1002/Syn.21801 |
0.456 |
|
| 2015 |
Huot P, Johnston TH, Koprich JB, Espinosa MC, Reyes MG, Fox SH, Brotchie JM. L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat. Behavioural Pharmacology. 26: 101-8. PMID 25303957 DOI: 10.1097/Fbp.0000000000000096 |
0.416 |
|
| 2014 |
Thiele SL, Chen B, Lo C, Gertler TS, Warre R, Surmeier JD, Brotchie JM, Nash JE. Selective loss of bi-directional synaptic plasticity in the direct and indirect striatal output pathways accompanies generation of parkinsonism and l-DOPA induced dyskinesia in mouse models. Neurobiology of Disease. 71: 334-44. PMID 25171793 DOI: 10.1016/J.Nbd.2014.08.006 |
0.325 |
|
| 2014 |
Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology. 82: 76-87. PMID 24447715 DOI: 10.1016/J.Neuropharm.2014.01.012 |
0.46 |
|
| 2013 |
Eskow Jaunarajs KL, Standaert DG, Viegas TX, Bentley MD, Fang Z, Dizman B, Yoon K, Weimer R, Ravenscroft P, Johnston TH, Hill MP, Brotchie JM, Moreadith RW. Rotigotine polyoxazoline conjugate SER-214 provides robust and sustained antiparkinsonian benefit. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1675-82. PMID 24014074 DOI: 10.1002/Mds.25625 |
0.47 |
|
| 2013 |
Johnston TH, Huot P, Fox SH, Koprich JB, Szeliga KT, James JW, Graef JD, Letchworth SR, Jordan KG, Hill MP, Brotchie JM. TC-8831, a nicotinic acetylcholine receptor agonist, reduces L-DOPA-induced dyskinesia in the MPTP macaque. Neuropharmacology. 73: 337-47. PMID 23770260 DOI: 10.1016/J.Neuropharm.2013.06.005 |
0.442 |
|
| 2013 |
Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacological Reviews. 65: 171-222. PMID 23319549 DOI: 10.1124/Pr.111.005678 |
0.489 |
|
| 2013 |
Koprich JB, Huot P, Fox SH, Jarvie K, Lang AE, Seeman P, Brotchie JM. The effects of fast-off-D2 receptor antagonism on L-DOPA-induced dyskinesia and psychosis in parkinsonian macaques. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 43: 151-6. PMID 23306217 DOI: 10.1016/J.Pnpbp.2012.12.008 |
0.508 |
|
| 2013 |
Huot P, Johnston TH, Snoeren T, Koprich JB, Hill MP, Fox SH, Brotchie JM. Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque. The European Journal of Neuroscience. 37: 831-8. PMID 23281915 DOI: 10.1111/Ejn.12093 |
0.396 |
|
| 2013 |
Kalia LV, Brotchie JM, Fox SH. Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 131-44. PMID 23225267 DOI: 10.1002/mds.25273 |
0.416 |
|
| 2013 |
Sutton AC, Yu W, Calos ME, Mueller LE, Berk M, Shim J, Molho ES, Brotchie JM, Carlen PL, Shin DS. Elevated potassium provides an ionic mechanism for deep brain stimulation in the hemiparkinsonian rat. The European Journal of Neuroscience. 37: 231-41. PMID 23121286 DOI: 10.1111/Ejn.12040 |
0.373 |
|
| 2013 |
Sutton AC, Yu W, Calos ME, Smith AB, Ramirez-Zamora A, Molho ES, Pilitsis JG, Brotchie JM, Shin DS. Deep brain stimulation of the substantia nigra pars reticulata improves forelimb akinesia in the hemiparkinsonian rat. Journal of Neurophysiology. 109: 363-74. PMID 23076106 DOI: 10.1152/Jn.00311.2012 |
0.377 |
|
| 2013 |
Johnston TH, Huot P, Damude S, Fox SH, Jones SW, Rusche JR, Brotchie JM. RGFP109, a histone deacetylase inhibitor attenuates L-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: a proof-of-concept study. Parkinsonism & Related Disorders. 19: 260-4. PMID 22901956 DOI: 10.1016/J.Parkreldis.2012.07.001 |
0.429 |
|
| 2012 |
Huot P, Johnston TH, Gandy MN, Reyes MG, Fox SH, Piggott MJ, Brotchie JM. The monoamine re-uptake inhibitor UWA-101 improves motor fluctuations in the MPTP-lesioned common marmoset. Plos One. 7: e45587. PMID 23029119 DOI: 10.1371/Journal.Pone.0045587 |
0.45 |
|
| 2012 |
Fox SH, Johnston TH, Li Q, Brotchie J, Bezard E. A critique of available scales and presentation of the Non-Human Primate Dyskinesia Rating Scale. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 1373-8. PMID 22976821 DOI: 10.1002/mds.25133 |
0.659 |
|
| 2012 |
Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. Neuropharmacology. 63: 829-36. PMID 22722022 DOI: 10.1016/J.Neuropharm.2012.06.012 |
0.421 |
|
| 2012 |
Huot P, Johnston TH, Koprich JB, Aman A, Fox SH, Brotchie JM. L-745,870 reduces L-DOPA-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 342: 576-85. PMID 22619253 DOI: 10.1124/Jpet.112.195693 |
0.446 |
|
| 2012 |
Huot P, Johnston TH, Visanji NP, Darr T, Pires D, Hazrati LN, Brotchie JM, Fox SH. Increased levels of 5-HT1A receptor binding in ventral visual pathways in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 27: 735-42. PMID 22419526 DOI: 10.1002/Mds.24964 |
0.341 |
|
| 2012 |
Johnston TH, Millar Z, Huot P, Wagg K, Thiele S, Salomonczyk D, Yong-Kee CJ, Gandy MN, McIldowie M, Lewis KD, Gomez-Ramirez J, Lee J, Fox SH, Martin-Iverson M, Nash JE, ... ... Brotchie JM, et al. A novel MDMA analogue, UWA-101, that lacks psychoactivity and cytotoxicity, enhances L-DOPA benefit in parkinsonian primates. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 26: 2154-63. PMID 22345403 DOI: 10.1096/Fj.11-195016 |
0.466 |
|
| 2012 |
Rascol O, Ferreira J, Nègre-Pages L, Perez-Lloret S, Lacomblez L, Galitzky M, Lemarié JC, Corvol JC, Brotchie JM, Bossi L. A proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson's disease. Fundamental & Clinical Pharmacology. 26: 557-64. PMID 21585523 DOI: 10.1111/j.1472-8206.2011.00951.x |
0.339 |
|
| 2012 |
Alachkar A, Brotchie JM, Jones OT. Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia. Journal of Molecular Neuroscience : Mn. 46: 145-52. PMID 21562737 DOI: 10.1007/s12031-011-9539-x |
0.405 |
|
| 2012 |
Huot P, Johnston TH, Koprich JB, Winkelmolen L, Fox SH, Brotchie JM. Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque. Neurobiology of Aging. 33: 207.e9-19. PMID 21051107 DOI: 10.1016/J.Neurobiolaging.2010.09.011 |
0.441 |
|
| 2012 |
Huot P, Johnston TH, Winkelmolen L, Fox SH, Brotchie JM. 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA. Neurobiology of Aging. 33: 194.e5-15. PMID 20561716 DOI: 10.1016/J.Neurobiolaging.2010.04.035 |
0.406 |
|
| 2012 |
Koprich J, Johnston T, Huot P, Brotchie J. 3.118 PRIMATE AND RODENT MODELS OF PARKINSON'S DISEASE BASED ON VIRAL VECTOR MEDIATED OVEREXPRESSION OF ALPHA SYNUCLEIN Parkinsonism & Related Disorders. 18: S193. DOI: 10.1016/S1353-8020(11)70834-3 |
0.371 |
|
| 2012 |
Johnston T, Koprich J, Fox S, Meyers N, Ward C, Hickling R, Howson P, Brotchie J. 2.230 PYM50028, AN ORALLY ACTIVE NEUROTROPHIC FACTOR MODULATOR, ENHANCES THE EFFECT OF L-DOPA AND REDUCES L-DOPA-INDUCED DYSKINESIA IN MPTP-LESIONED MACAQUES Parkinsonism & Related Disorders. 18: S122. DOI: 10.1016/S1353-8020(11)70554-5 |
0.367 |
|
| 2012 |
Huot P, Koprich J, Johnston T, Fox S, Brotchie J. 2.217 PHARMACOKINETIC PROFILE OF THE SELECTIVE DOPAMINE D4 RECEPTOR ANTAGONIST L-745,870 IN THE MPTP-LESIONED NON-HUMAN PRIMATE MODEL OF PARKINSON'S DISEASE Parkinsonism & Related Disorders. 18: S119. DOI: 10.1016/S1353-8020(11)70541-7 |
0.526 |
|
| 2011 |
Brotchie J, Jenner P. New approaches to therapy. International Review of Neurobiology. 98: 123-50. PMID 21907085 DOI: 10.1016/B978-0-12-381328-2.00005-5 |
0.447 |
|
| 2011 |
Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson's disease. Progress in Neurobiology. 95: 163-212. PMID 21878363 DOI: 10.1016/J.Pneurobio.2011.08.004 |
0.436 |
|
| 2011 |
Huot P, Brotchie JM. 5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms. Experimental Neurology. 231: 195-8. PMID 21819982 DOI: 10.1016/J.Expneurol.2011.07.006 |
0.408 |
|
| 2011 |
Huot P, Fox SH, Newman-Tancredi A, Brotchie JM. Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism? The Journal of Pharmacology and Experimental Therapeutics. 339: 2-8. PMID 21784889 DOI: 10.1124/Jpet.111.184093 |
0.353 |
|
| 2011 |
Hilker R, Brotchie JM, Chapman J. Pros and cons of a prion-like pathogenesis in Parkinson's disease. Bmc Neurology. 11: 74. PMID 21689433 DOI: 10.1186/1471-2377-11-74 |
0.412 |
|
| 2011 |
Huot P, Johnston TH, Lewis KD, Koprich JB, Reyes MG, Fox SH, Piggott MJ, Brotchie JM. Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 7190-8. PMID 21562283 DOI: 10.1523/Jneurosci.1171-11.2011 |
0.438 |
|
| 2011 |
Koprich JB, Fox SH, Johnston TH, Goodman A, Le Bourdonnec B, Dolle RE, DeHaven RN, DeHaven-Hudkins DL, Little PJ, Brotchie JM. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 26: 1225-33. PMID 21465551 DOI: 10.1002/mds.23631 |
0.466 |
|
| 2011 |
Koprich JB, Johnston TH, Huot P, Reyes MG, Espinosa M, Brotchie JM. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. Plos One. 6: e17698. PMID 21408191 DOI: 10.1371/Journal.Pone.0017698 |
0.472 |
|
| 2011 |
Thiele SL, Warre R, Khademullah CS, Fahana N, Lo C, Lam D, Talwar S, Johnston TH, Brotchie JM, Nash JE. Generation of a model of L-DOPA-induced dyskinesia in two different mouse strains. Journal of Neuroscience Methods. 197: 193-208. PMID 21352853 DOI: 10.1016/J.Jneumeth.2011.02.012 |
0.388 |
|
| 2011 |
Warre R, Thiele S, Talwar S, Kamal M, Johnston TH, Wang S, Lam D, Lo C, Khademullah CS, Perera G, Reyes G, Sun XS, Brotchie JM, Nash JE. Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism. Neurobiology of Disease. 41: 591-604. PMID 20971190 DOI: 10.1016/J.Nbd.2010.10.013 |
0.409 |
|
| 2011 |
Johnston TH, Huot P, Fox SH, Wakefield JD, Sykes KA, Bartolini WP, Milne GT, Pearson JP, Brotchie JM. Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 336: 423-30. PMID 20966038 DOI: 10.1124/Jpet.110.169532 |
0.466 |
|
| 2011 |
Fox SH, Brotchie JM. Non-Dopaminergic Approaches to the Treatment of Parkinson's Disease Parkinson's Disease: Non-Motor and Non-Dopaminergic Features. 432-454. DOI: 10.1002/9781444397970.ch38 |
0.314 |
|
| 2010 |
Koprich JB, Johnston TH, Reyes MG, Sun X, Brotchie JM. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. Molecular Neurodegeneration. 5: 43. PMID 21029459 DOI: 10.1186/1750-1326-5-43 |
0.416 |
|
| 2010 |
Fox SH, Brotchie JM. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. Progress in Brain Research. 184: 133-57. PMID 20887873 DOI: 10.1016/S0079-6123(10)84007-5 |
0.462 |
|
| 2010 |
Johnston TH, Fox SH, Piggott MJ, Savola JM, Brotchie JM. The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 2084-93. PMID 20824735 DOI: 10.1002/mds.23172 |
0.41 |
|
| 2010 |
Huot P, Johnston TH, Darr T, Hazrati LN, Visanji NP, Pires D, Brotchie JM, Fox SH. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1399-408. PMID 20629135 DOI: 10.1002/Mds.23083 |
0.369 |
|
| 2010 |
Alachkar A, Brotchie JM, Jones OT. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites. Neuroscience Research. 68: 44-50. PMID 20542064 DOI: 10.1016/j.neures.2010.06.003 |
0.467 |
|
| 2010 |
Johnston TH, van der Meij A, Brotchie JM, Fox SH. Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 25: 1379-90. PMID 20310030 DOI: 10.1002/mds.23069 |
0.39 |
|
| 2010 |
Alachkar A, Brotchie JM, Jones OT. Binding of dopamine and 3-methoxytyramine as l-DOPA metabolites to human alpha(2)-adrenergic and dopaminergic receptors. Neuroscience Research. 67: 245-9. PMID 20302892 DOI: 10.1016/j.neures.2010.03.008 |
0.442 |
|
| 2010 |
Johnston TH, Fox SH, McIldowie MJ, Piggott MJ, Brotchie JM. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 333: 865-73. PMID 20231306 DOI: 10.1124/jpet.110.166629 |
0.475 |
|
| 2010 |
Fox SH, Visanji N, Reyes G, Huot P, Gomez-Ramirez J, Johnston T, Brotchie JM. Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson's disease. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 37: 86-95. PMID 20169779 DOI: 10.1017/S0317167100009707 |
0.459 |
|
| 2010 |
Silverdale MA, Kobylecki C, Hallett PJ, Li Q, Dunah AW, Ravenscroft P, Bezard E, Brotchie JM. Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse (New York, N.Y.). 64: 177-80. PMID 19852073 DOI: 10.1002/syn.20739 |
0.66 |
|
| 2009 |
Koprich JB, Johnston TH, Huot P, Fox SH, Brotchie JM. New insights into the organization of the basal ganglia. Current Neurology and Neuroscience Reports. 9: 298-304. PMID 19515282 DOI: 10.1007/S11910-009-0045-2 |
0.342 |
|
| 2009 |
Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson's disease: On movement, mood, and madness. Movement Disorders : Official Journal of the Movement Disorder Society. 24: 1255-66. PMID 19412960 DOI: 10.1002/mds.22473 |
0.381 |
|
| 2009 |
Brotchie J, Fitzer-Attas C. Mechanisms compensating for dopamine loss in early Parkinson disease Neurology. 72: S32-S38. PMID 19221312 DOI: 10.1212/WNL.0b013e318198e0e9 |
0.483 |
|
| 2009 |
Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Neurobiology of Disease. 35: 184-92. PMID 19118628 DOI: 10.1016/j.nbd.2008.11.010 |
0.509 |
|
| 2009 |
Visanji NP, Fox SH, Johnston TH, Millan MJ, Brotchie JM. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques. The Journal of Pharmacology and Experimental Therapeutics. 328: 276-83. PMID 18955589 DOI: 10.1124/jpet.108.144097 |
0.424 |
|
| 2008 |
Fox SH, Brotchie JM, Lang AE. Non-dopaminergic treatments in development for Parkinson's disease. The Lancet. Neurology. 7: 927-38. PMID 18848312 DOI: 10.1016/S1474-4422(08)70214-X |
0.431 |
|
| 2008 |
Fox SH, Chuang R, Brotchie JM. Parkinson's disease--opportunities for novel therapeutics to reduce the problems of levodopa therapy. Progress in Brain Research. 172: 479-94. PMID 18772047 DOI: 10.1016/S0079-6123(08)00923-0 |
0.442 |
|
| 2008 |
Visanji NP, de Bie RM, Johnston TH, McCreary AC, Brotchie JM, Fox SH. The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 1922-5. PMID 18759357 DOI: 10.1002/mds.22086 |
0.519 |
|
| 2008 |
Lopez S, Turle-Lorenzo N, Johnston TH, Brotchie JM, Schann S, Neuville P, Amalric M. Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. Neuropharmacology. 55: 483-90. PMID 18625257 DOI: 10.1016/j.neuropharm.2008.06.038 |
0.486 |
|
| 2008 |
Nicholas AP, Lubin FD, Hallett PJ, Vattem P, Ravenscroft P, Bezard E, Zhou S, Fox SH, Brotchie JM, Sweatt JD, Standaert DG. Striatal histone modifications in models of levodopa-induced dyskinesia. Journal of Neurochemistry. 106: 486-94. PMID 18410512 DOI: 10.1111/j.1471-4159.2008.05417.x |
0.647 |
|
| 2008 |
Visanji NP, Orsi A, Johnston TH, Howson PA, Dixon K, Callizot N, Brotchie JM, Rees DD. PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 22: 2488-97. PMID 18364399 DOI: 10.1096/fj.07-095398 |
0.432 |
|
| 2008 |
Lee J, Gomez-Ramirez J, Johnston TH, Visanji N, Brotchie JM. Receptor-activity modifying protein 1 expression is increased in the striatum following repeated L-DOPA administration in a 6-hydroxydopamine lesioned rat model of Parkinson's disease. Synapse (New York, N.Y.). 62: 310-3. PMID 18241048 DOI: 10.1002/syn.20481 |
0.492 |
|
| 2008 |
Brotchie JM. Pharmacology of Parkinson's Disease Therapeutics of Parkinson's Disease and Other Movement Disorders. 37-48. DOI: 10.1002/9780470713990.ch3 |
0.32 |
|
| 2007 |
Shin DS, Samoilova M, Cotic M, Zhang L, Brotchie JM, Carlen PL. High frequency stimulation or elevated K+ depresses neuronal activity in the rat entopeduncular nucleus. Neuroscience. 149: 68-86. PMID 17826920 DOI: 10.1016/J.Neuroscience.2007.06.055 |
0.325 |
|
| 2007 |
Fabbrini G, Brotchie JM, Grandas F, Nomoto M, Goetz CG. Levodopa-induced dyskinesias. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 1379-89; quiz 1523. PMID 17427940 DOI: 10.1002/mds.21475 |
0.445 |
|
| 2007 |
Hallett PJ, Brotchie JM. Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia. Movement Disorders : Official Journal of the Movement Disorder Society. 22: 28-40. PMID 17089424 DOI: 10.1002/mds.21163 |
0.455 |
|
| 2007 |
Brotchie J, Johnston T, Visanji N, Pires D, Thiele S, Fitzer-Attas C, Pereira Montezinho L, Mørk A, Thomsen C. 2.217 1-Aminoindan, a main metabolite of rasagiline, enhances dopamine release and provides symptomatic benefit in an animal model of Parkinson's disease Parkinsonism & Related Disorders. 13: S102. DOI: 10.1016/S1353-8020(08)70628-X |
0.465 |
|
| 2006 |
Schapira AH, Bezard E, Brotchie J, Calon F, Collingridge GL, Ferger B, Hengerer B, Hirsch E, Jenner P, Le Novère N, Obeso JA, Schwarzschild MA, Spampinato U, Davidai G. Novel pharmacological targets for the treatment of Parkinson's disease. Nature Reviews. Drug Discovery. 5: 845-54. PMID 17016425 DOI: 10.1038/Nrd2087 |
0.721 |
|
| 2006 |
Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 2090-5. PMID 16991143 DOI: 10.1002/mds.21106 |
0.747 |
|
| 2006 |
Fox SH, Visanji NP, Johnston TH, Gomez-Ramirez J, Voon V, Brotchie JM. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Archives of Neurology. 63: 1343-4. PMID 16966523 DOI: 10.1001/archneur.63.9.1343 |
0.509 |
|
| 2006 |
Visanji NP, Gomez-Ramirez J, Johnston TH, Pires D, Voon V, Brotchie JM, Fox SH. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1879-91. PMID 16960862 DOI: 10.1002/mds.21073 |
0.385 |
|
| 2006 |
Nadjar A, Brotchie JM, Guigoni C, Li Q, Zhou SB, Wang GJ, Ravenscroft P, Georges F, Crossman AR, Bezard E. Phenotype of striatofugal medium spiny neurons in parkinsonian and dyskinetic nonhuman primates: a call for a reappraisal of the functional organization of the basal ganglia. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 26: 8653-61. PMID 16928853 DOI: 10.1523/Jneurosci.2582-06.2006 |
0.809 |
|
| 2006 |
Fox SH, Lang AE, Brotchie JM. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: keys to success and roads to failure. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 1578-94. PMID 16874752 DOI: 10.1002/mds.20936 |
0.317 |
|
| 2006 |
Visanji NP, Millan MJ, Brotchie JM. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats. Experimental Neurology. 202: 85-92. PMID 16814282 DOI: 10.1016/j.expneurol.2006.05.016 |
0.474 |
|
| 2006 |
Lee J, Di Marzo V, Brotchie JM. A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats. Neuropharmacology. 51: 557-65. PMID 16806299 DOI: 10.1016/j.neuropharm.2006.04.016 |
0.415 |
|
| 2006 |
Gomez-Ramirez J, Johnston TH, Visanji NP, Fox SH, Brotchie JM. Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 21: 839-46. PMID 16532454 DOI: 10.1002/mds.20828 |
0.532 |
|
| 2006 |
Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease: an update. Current Opinion in Investigational Drugs (London, England : 2000). 7: 25-32. PMID 16425668 |
0.314 |
|
| 2006 |
Alachkar A, Brotchie J, Jones OT. α2-Adrenoceptor-mediated modulation of the release of GABA and noradrenaline in the rat substantia nigra pars reticulata Neuroscience Letters. 395: 138-142. PMID 16356632 DOI: 10.1016/j.neulet.2005.10.069 |
0.346 |
|
| 2005 |
Visanji NP, Brotchie JM. MPTP-induced models of Parkinson's disease in mice and non-human primates. Current Protocols in Pharmacology / Editorial Board, S.J. Enna (Editor-in-Chief) ... [Et Al.]. Unit5.42. PMID 21953394 DOI: 10.1002/0471141755.ph0542s29 |
0.444 |
|
| 2005 |
Johnston TH, Fox SH, Brotchie JM. Advances in the delivery of treatments for Parkinson's disease. Expert Opinion On Drug Delivery. 2: 1059-73. PMID 16296809 DOI: 10.1517/17425247.2.6.1059 |
0.426 |
|
| 2005 |
Brotchie JM. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 919-31. PMID 16007614 DOI: 10.1002/mds.20612 |
0.442 |
|
| 2005 |
Venderova K, Brown TM, Brotchie JM. Differential effects of endocannabinoids on [(3)H]-GABA uptake in the rat globus pallidus. Experimental Neurology. 194: 284-7. PMID 15899265 DOI: 10.1016/J.Expneurol.2005.02.012 |
0.534 |
|
| 2005 |
van der Stelt M, Fox SH, Hill M, Crossman AR, Petrosino S, Di Marzo V, Brotchie JM. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 19: 1140-2. PMID 15894565 DOI: 10.1096/fj.04-3010fje |
0.786 |
|
| 2005 |
Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, Brotchie JM, Standaert DG. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology. 48: 503-16. PMID 15755478 DOI: 10.1016/j.neuropharm.2004.11.008 |
0.82 |
|
| 2005 |
Nash JE, Johnston TH, Collingridge GL, Garner CC, Brotchie JM. Subcellular redistribution of the synapse-associated proteins PSD-95 and SAP97 in animal models of Parkinson's disease and L-DOPA-induced dyskinesia. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 19: 583-5. PMID 15703272 DOI: 10.1096/fj.04-1854fje |
0.481 |
|
| 2005 |
Johnston TH, Lee J, Gomez-Ramirez J, Fox SH, Brotchie JM. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease. Experimental Neurology. 191: 243-50. PMID 15649479 DOI: 10.1016/j.expneurol.2004.10.002 |
0.453 |
|
| 2005 |
Brotchie JM, Lee J, Venderova K. Levodopa-induced dyskinesia in Parkinson's disease. Journal of Neural Transmission (Vienna, Austria : 1996). 112: 359-91. PMID 15614429 DOI: 10.1007/s00702-004-0251-7 |
0.446 |
|
| 2005 |
Silverdale MA, Nicholson SL, Crossman AR, Brotchie JM. Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 20: 403-9. PMID 15593312 DOI: 10.1002/mds.20345 |
0.78 |
|
| 2005 |
Brown T, de Groote C, Brotchie J. Recent advances in the treatment of L-DOPA-induced dyskinesia. Idrugs : the Investigational Drugs Journal. 5: 454-68. PMID 15570465 |
0.621 |
|
| 2004 |
Hill MP, Brotchie JM, Crossman AR, Bezard E, Michel A, Grimée R, Klitgaard H. Levetiracetam Interferes With the L-dopa priming process in MPTP-lesioned drug-naive marmosets. Clinical Neuropharmacology. 27: 171-7. PMID 15319703 DOI: 10.1097/01.wnf.0000135478.70905.3d |
0.778 |
|
| 2004 |
Ismayilova N, Crossman A, Verkhratsky A, Brotchie J. Effects of adenosine A 1, dopamine D1 and metabotropic glutamate 5 receptors-modulating agents on locomotion of the reserpinised rats European Journal of Pharmacology. 497: 187-195. PMID 15306204 DOI: 10.1016/j.ejphar.2004.06.030 |
0.756 |
|
| 2004 |
Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease. Current Opinion in Investigational Drugs (London, England : 2000). 5: 720-6. PMID 15298067 |
0.404 |
|
| 2004 |
Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, Brotchie JM. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Experimental Neurology. 188: 471-9. PMID 15246846 DOI: 10.1016/J.Expneurol.2004.05.004 |
0.758 |
|
| 2004 |
Silverdale MA, Nicholson SL, Ravenscroft P, Crossman AR, Millan MJ, Brotchie JM. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate. Experimental Neurology. 188: 128-38. PMID 15191809 DOI: 10.1016/j.expneurol.2004.03.022 |
0.755 |
|
| 2004 |
Fox S, Silverdale M, Kellett M, Davies R, Steiger M, Fletcher N, Crossman A, Brotchie J. Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease Movement Disorders. 19: 554-560. PMID 15133820 DOI: 10.1002/mds.10693 |
0.748 |
|
| 2004 |
Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease. The Journal of Pharmacology and Experimental Therapeutics. 310: 386-94. PMID 15004218 DOI: 10.1124/jpet.104.066191 |
0.815 |
|
| 2004 |
Millan MJ, Di Cara B, Hill M, Jackson M, Joyce JN, Brotchie J, McGuire S, Crossman A, Smith L, Jenner P, Gobert A, Peglion JL, Brocco M. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole. The Journal of Pharmacology and Experimental Therapeutics. 309: 921-35. PMID 14978195 DOI: 10.1124/Jpet.103.062414 |
0.755 |
|
| 2004 |
Bezard E, Hill MP, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque. European Journal of Pharmacology. 485: 159-64. PMID 14757136 DOI: 10.1016/j.ejphar.2003.11.065 |
0.8 |
|
| 2004 |
Ravenscroft P, Chalon S, Brotchie JM, Crossman AR. Ropinirole versus L-DOPA effects on striatal opioid peptide precursors in a rodent model of Parkinson's disease: implications for dyskinesia. Experimental Neurology. 185: 36-46. PMID 14697317 DOI: 10.1016/j.expneurol.2003.09.001 |
0.778 |
|
| 2004 |
Bezard E, Gross CE, Brotchie JM. Response to Obeso et al.: Presymptomatic compensation in Parkinson's disease is not dopamine-mediated Trends in Neurosciences. 27: 127-128. DOI: 10.1016/j.tins.2003.12.005 |
0.728 |
|
| 2003 |
Brown TM, Brotchie JM, Fitzjohn SM. Cannabinoids decrease corticostriatal synaptic transmission via an effect on glutamate uptake. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 23: 11073-7. PMID 14657164 DOI: 10.1523/Jneurosci.23-35-11073.2003 |
0.738 |
|
| 2003 |
Hill MP, Bezard E, McGuire SG, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H. Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset. Movement Disorders : Official Journal of the Movement Disorder Society. 18: 1301-5. PMID 14639671 DOI: 10.1002/mds.10542 |
0.817 |
|
| 2003 |
Henry B, Duty S, Fox SH, Crossman AR, Brotchie JM. Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's disease. Experimental Neurology. 183: 458-68. PMID 14552886 DOI: 10.1016/S0014-4886(03)00064-5 |
0.755 |
|
| 2003 |
Bezard E, Baufreton J, Owens G, Crossman AR, Dudek H, Taupignon A, Brotchie JM. Sonic hedgehog is a neuromodulator in the adult subthalamic nucleus. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 17: 2337-8. PMID 14525941 DOI: 10.1096/fj.03-0291fje |
0.804 |
|
| 2003 |
Savola JM, Hill M, Engstrom M, Merivuori H, Wurster S, McGuire SG, Fox SH, Crossman AR, Brotchie JM. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 18: 872-83. PMID 12889076 DOI: 10.1002/mds.10464 |
0.731 |
|
| 2003 |
Bezard E, Gross CE, Brotchie JM. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends in Neurosciences. 26: 215-21. PMID 12689773 DOI: 10.1016/S0166-2236(03)00038-9 |
0.771 |
|
| 2003 |
Brotchie JM. CB1 cannabinoid receptor signalling in Parkinson's disease. Current Opinion in Pharmacology. 3: 54-61. PMID 12550742 DOI: 10.1016/S1471-4892(02)00011-5 |
0.499 |
|
| 2003 |
Segovia G, Mora F, Crossman AR, Brotchie JM. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 18: 138-49. PMID 12539206 DOI: 10.1002/mds.10312 |
0.755 |
|
| 2003 |
Silverdale MA, Fox SH, Crossman AR, Brotchie JM. Potential nondopaminergic drugs for Parkinson's disease. Advances in Neurology. 91: 273-91. PMID 12442686 |
0.692 |
|
| 2003 |
Venderova K, Brotchie J, Brown T, Ruzicka E, Visnovsky P. Endocannabinoids, their effect on GABA uptake in globus pallidus and relevance to Parkinson's disease Journal of Neurochemistry. 85: 37-37. DOI: 10.1046/J.1471-4159.85.S2.22_15.X |
0.583 |
|
| 2002 |
Fox SH, Henry B, Hill M, Crossman A, Brotchie J. Stimulation of Cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease Movement Disorders. 17: 1180-1187. PMID 12465055 DOI: 10.1002/mds.10289 |
0.795 |
|
| 2002 |
Nicholson SL, Brotchie JM. 5-hydroxytryptamine (5-HT, serotonin) and Parkinson's disease - opportunities for novel therapeutics to reduce the problems of levodopa therapy. European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies. 9: 1-6. PMID 12464115 DOI: 10.1046/j.1468-1331.2002.00272.x |
0.45 |
|
| 2002 |
Nash JE, Brotchie JM. Characterisation of striatal NMDA receptors involved in the generation of parkinsonian symptoms: intrastriatal microinjection studies in the 6-OHDA-lesioned rat. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 455-66. PMID 12112191 DOI: 10.1002/Mds.10107 |
0.515 |
|
| 2002 |
Davis S, Brotchie J, Davies I. Protection of striatal neurons by joint blockade of D1 and D2 receptor subtypes in an in vitro model of cerebral hypoxia. Experimental Neurology. 176: 229-36. PMID 12093100 DOI: 10.1006/exnr.2002.7926 |
0.443 |
|
| 2002 |
Silverdale MA, Crossman AR, Brotchie JM. Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia. Experimental Neurology. 174: 21-8. PMID 11869030 DOI: 10.1006/exnr.2001.7854 |
0.777 |
|
| 2002 |
Fox SH, Kellett M, Moore AP, Crossman AR, Brotchie JM. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Movement Disorders : Official Journal of the Movement Disorder Society. 17: 145-9. PMID 11835452 DOI: 10.1002/mds.1280 |
0.723 |
|
| 2001 |
Sieradzan KA, Fox SH, Hill M, Dick JP, Crossman AR, Brotchie JM. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology. 57: 2108-11. PMID 11739835 DOI: 10.1212/Wnl.57.11.2108 |
0.744 |
|
| 2001 |
Hille CJ, Fox SH, Maneuf YP, Crossman AR, Brotchie JM. Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease. Experimental Neurology. 172: 189-98. PMID 11681851 DOI: 10.1006/exnr.2001.7763 |
0.777 |
|
| 2001 |
Henry B, Fox SH, Crossman AR, Brotchie JM. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Experimental Neurology. 171: 139-46. PMID 11520128 DOI: 10.1006/exnr.2001.7727 |
0.762 |
|
| 2001 |
Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 21: 6853-61. PMID 11517273 DOI: 10.1523/Jneurosci.21-17-06853.2001 |
0.823 |
|
| 2001 |
Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nature Reviews. Neuroscience. 2: 577-88. PMID 11484001 DOI: 10.1038/35086062 |
0.724 |
|
| 2001 |
Fox SH, Henry B, Hill MP, Peggs D, Crossman AR, Brotchie JM. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 642-50. PMID 11481687 DOI: 10.1002/mds.1148 |
0.78 |
|
| 2001 |
Silverdale MA, McGuire S, McInnes A, Crossman AR, Brotchie JM. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Experimental Neurology. 169: 400-6. PMID 11358453 DOI: 10.1006/exnr.2001.7649 |
0.76 |
|
| 2001 |
Bezard E, Boraud T, Chalon S, Brotchie JM, Guilloteau D, Gross CE. Pallidal border cells: an anatomical and electrophysiological study in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey. Neuroscience. 103: 117-23. PMID 11311792 DOI: 10.1016/S0306-4522(00)00546-7 |
0.725 |
|
| 2001 |
Bezard E, Ravenscroft P, Gross CE, Crossman AR, Brotchie JM. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine monkeys. Neurobiology of Disease. 8: 343-50. PMID 11300729 DOI: 10.1006/nbdi.2000.0375 |
0.828 |
|
| 2001 |
Bezard E, Crossman AR, Gross CE, Brotchie JM. Structures outside the basal ganglia may compensate for dopamine loss in the presymptomatic stages of Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 15: 1092-4. PMID 11292678 DOI: 10.1096/Fj.00-0637Fje |
0.821 |
|
| 2001 |
Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE. Relationship between the Appearance of Symptoms and the Level of Nigrostriatal Degeneration in a Progressive 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease The Journal of Neuroscience. 21: 6853-6861. DOI: 10.1523/JNEUROSCI.21-17-06853.2001 |
0.805 |
|
| 2000 |
Hill MP, Hille CJ, Brotchie JM. Delta-opioid receptor agonists as a therapeutic approach in Parkinson's disease. Drug News & Perspectives. 13: 261-8. PMID 12937640 |
0.4 |
|
| 2000 |
Fox SH, Brotchie JM. 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 15: 1064-9. PMID 11104187 DOI: 10.1002/1531-8257(200011)15:6<1064::AID-MDS1002>3.0.CO;2-C |
0.487 |
|
| 2000 |
Nash JE, Brotchie JM. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 7782-9. PMID 11027242 DOI: 10.1523/Jneurosci.20-20-07782.2000 |
0.443 |
|
| 2000 |
Nash JE, Fox SH, Henry B, Hill MP, Peggs D, McGuire S, Maneuf Y, Hille C, Brotchie JM, Crossman AR. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease. Experimental Neurology. 165: 136-42. PMID 10964492 DOI: 10.1006/Exnr.2000.7444 |
0.786 |
|
| 2000 |
Ravenscroft P, Brotchie J. NMDA receptors in the basal ganglia. Journal of Anatomy. 577-85. PMID 10923988 DOI: 10.1046/j.1469-7580.2000.19640577.x |
0.415 |
|
| 2000 |
Di Marzo V, Hill MP, Bisogno T, Crossman AR, Brotchie JM. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 14: 1432-8. PMID 10877836 DOI: 10.1096/Fasebj.14.10.1432 |
0.769 |
|
| 2000 |
Fox SH, Brotchie JM. 5-HT(2C) receptor antagonists enhance the behavioural response to dopamine D(1) receptor agonists in the 6-hydroxydopamine-lesioned rat. European Journal of Pharmacology. 398: 59-64. PMID 10856448 DOI: 10.1016/S0014-2999(00)00238-7 |
0.547 |
|
| 2000 |
Brotchie JM. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. Annals of Neurology. 47: S105-12; discussion . PMID 10762137 |
0.377 |
|
| 2000 |
Hill MP, Hille CJ, Brotchie JM. δ-Opioid receptor agonists as a therapeutic approach in Parkinson's disease Drug News and Perspectives. 13: 261-268. |
0.328 |
|
| 1999 |
Hill MP, Brotchie JM. The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat. British Journal of Pharmacology. 128: 1577-85. PMID 10602339 DOI: 10.1038/sj.bjp.0702943 |
0.487 |
|
| 1999 |
Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 14: 744-53. PMID 10495035 DOI: 10.1002/1531-8257(199909)14:5<744::AID-MDS1006>3.0.CO;2-7 |
0.78 |
|
| 1999 |
Henry B, Crossman AR, Brotchie JM. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat. Experimental Neurology. 155: 204-20. PMID 10072296 DOI: 10.1006/exnr.1998.6996 |
0.778 |
|
| 1999 |
Nash JE, Hill MP, Brotchie JM. Antiparkinsonian actions of blockade of NR2B-containing NMDA receptors in the reserpine-treated rat. Experimental Neurology. 155: 42-8. PMID 9918703 DOI: 10.1006/Exnr.1998.6963 |
0.482 |
|
| 1998 |
Brotchie JM. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 871-6. PMID 9827609 DOI: 10.1002/mds.870130603 |
0.525 |
|
| 1998 |
Henry B, Crossman AR, Brotchie JM. Characterization of a rodent model in which to investigate the molecular and cellular mechanisms underlying the pathophysiology of L-dopa-induced dyskinesia. Advances in Neurology. 78: 53-61. PMID 9750903 |
0.669 |
|
| 1998 |
Brotchie JM, Henry B, Hille CJ, Crossman AR. Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease. Advances in Neurology. 78: 41-52. PMID 9750902 |
0.714 |
|
| 1998 |
Crossman AR, Brotchie JM. Pathophysiology of dystonia. Advances in Neurology. 78: 19-25. PMID 9750899 |
0.644 |
|
| 1998 |
Richter A, Brotchie JM, Crossman AR, Löscher W. [3H]-2-deoxyglucose uptake study in mutant dystonic hamsters: abnormalities in discrete brain regions of the motor system. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 718-25. PMID 9686781 DOI: 10.1002/mds.870130419 |
0.712 |
|
| 1998 |
Henry B, Crossman AR, Brotchie JM. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Experimental Neurology. 151: 334-42. PMID 9628768 DOI: 10.1006/exnr.1998.6819 |
0.764 |
|
| 1998 |
Fox SH, Moser B, Brotchie JM. Behavioral effects of 5-HT2C receptor antagonism in the substantia nigra zona reticulata of the 6-hydroxydopamine-lesioned rat model of Parkinson's disease. Experimental Neurology. 151: 35-49. PMID 9582253 DOI: 10.1006/exnr.1998.6792 |
0.572 |
|
| 1998 |
Hughes NR, McKnight AT, Woodruff GN, Hill MP, Crossman AR, Brotchie JM. Kappa-opioid receptor agonists increase locomotor activity in the monoamine-depleted rat model of parkinsonism. Movement Disorders : Official Journal of the Movement Disorder Society. 13: 228-33. PMID 9539334 DOI: 10.1002/mds.870130206 |
0.723 |
|
| 1998 |
Duty S, Henry B, Crossman AR, Brotchie JM. Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat. Experimental Neurology. 150: 223-34. PMID 9527891 DOI: 10.1006/exnr.1997.6771 |
0.742 |
|
| 1997 |
Maneuf YP, Crossman AR, Brotchie JM. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease. Experimental Neurology. 148: 265-70. PMID 9398468 DOI: 10.1006/exnr.1997.6645 |
0.752 |
|
| 1997 |
Brotchie JM. Novel approaches to the symptomatic treatment of parkinsonian syndromes: alternatives and adjuncts to dopamine-replacement. Current Opinion in Neurology. 10: 340-5. PMID 9266159 DOI: 10.1097/00019052-199708000-00010 |
0.437 |
|
| 1997 |
Duty S, Brotchie JM. Enhancement of the behavioral response to apomorphine administration following repeated treatment in the 6-hydroxydopamine-lesioned rat is temporally correlated with a rise in striatal preproenkephalin-B, but not preproenkephalin-A, gene expression. Experimental Neurology. 144: 423-32. PMID 9168843 DOI: 10.1006/exnr.1997.6431 |
0.421 |
|
| 1997 |
Maneuf YP, Brotchie JM. Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. British Journal of Pharmacology. 120: 1397-8. PMID 9113356 DOI: 10.1038/sj.bjp.0701101 |
0.309 |
|
| 1997 |
Glass M, Brotchie JM, Maneuf YP. Modulation of neurotransmission by cannabinoids in the basal ganglia. The European Journal of Neuroscience. 9: 199-203. PMID 9058040 DOI: 10.1111/j.1460-9568.1997.tb01390.x |
0.334 |
|
| 1997 |
Fox S, Brotchie J. Normethylclozapine potentiates the action of quinpirole in the 6-hydroxydopamine lesioned rat. European Journal of Pharmacology. 301: 27-30. PMID 8773443 DOI: 10.1016/0014-2999(96)00100-8 |
0.518 |
|
| 1996 |
East SJ, Parry-Jones A, Brotchie JM. Ionotropic glutamate receptors and nitric oxide synthesis in the rat striatum. Neuroreport. 8: 71-5. PMID 9051755 DOI: 10.1097/00001756-199612200-00015 |
0.42 |
|
| 1996 |
Fox SH, Brotchie JM. New treatments for movement disorders? Trends in Pharmacological Sciences. 17: 339-42. PMID 8979766 DOI: 10.1016/S0165-6147(96)30018-7 |
0.465 |
|
| 1996 |
Henry B, Brotchie JM. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs & Aging. 9: 149-58. PMID 8877309 DOI: 10.2165/00002512-199609030-00001 |
0.511 |
|
| 1996 |
Maneuf YP, Crossman AR, Brotchie JM. Modulation of GABAergic transmission in the globus pallidus by the synthetic cannabinoid WIN 55,212-2. Synapse (New York, N.Y.). 22: 382-5. PMID 8867032 DOI: 10.1002/(SICI)1098-2396(199604)22:4<382::AID-SYN9>3.0.CO;2-7 |
0.669 |
|
| 1996 |
Maneuf YP, Nash JE, Crossman AR, Brotchie JM. Activation of the cannabinoid receptor by delta 9-tetrahydrocannabinol reduces gamma-aminobutyric acid uptake in the globus pallidus. European Journal of Pharmacology. 308: 161-4. PMID 8840127 DOI: 10.1016/0014-2999(96)00326-3 |
0.685 |
|
| 1996 |
Maneuf YP, Duty S, Hille CJ, Crossman AR, Brotchie JM. Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's disease. Experimental Neurology. 139: 12-6. PMID 8635558 DOI: 10.1006/exnr.1996.0075 |
0.715 |
|
| 1995 |
Mitchell IJ, Hughes N, Carroll CB, Brotchie JM. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behavioural Pharmacology. 6: 492-507. PMID 11224357 |
0.331 |
|
| 1995 |
Hill MP, Brotchie JM. Modulation of glutamate release by a kappa-opioid receptor agonist in rodent and primate striatum. European Journal of Pharmacology. 281: R1-R2. PMID 8566106 DOI: 10.1016/0014-2999(95)00385-X |
0.401 |
|
| 1995 |
Carroll CB, Holloway V, Brotchie JM, Mitchell IJ. Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms. Psychopharmacology. 119: 55-65. PMID 7675950 DOI: 10.1007/BF02246054 |
0.418 |
|
| 1995 |
East SJ, Hill MP, Brotchie JM. Metabotropic glutamate receptor agonists inhibit endogenous glutamate release from rat striatal synaptosomes. European Journal of Pharmacology. 277: 117-21. PMID 7635167 DOI: 10.1016/0014-2999(95)00119-6 |
0.402 |
|
| 1995 |
Maneuf YP, Mitchell IJ, Crossman AR, Woodruff GN, Brotchie JM. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Research. 683: 102-8. PMID 7552334 DOI: 10.1016/0006-8993(95)00358-W |
0.78 |
|
| 1994 |
Maneuf YP, Mitchell IJ, Crossman AR, Brotchie JM. On the role of enkephalin cotransmission in the GABAergic striatal efferents to the globus pallidus. Experimental Neurology. 125: 65-71. PMID 8307125 DOI: 10.1006/exnr.1994.1007 |
0.736 |
|
| 1993 |
Brotchie J, Crossman A, Mitchell I, Duty S, Carroll C, Cooper A, Henry B, Hughes N, Maneuf Y. Chemical signalling in the globus pallidus in parkinsonism Progress in Brain Research. 99: 125-139. PMID 7906423 DOI: 10.1016/S0079-6123(08)61342-4 |
0.718 |
|
| 1992 |
MORELLI M, FENU S, PINNA A, PONTIERI F, DI CG, MITCHELL IJ, BROTCHIE JM, CROSSMAN AR. INTERACTION BETWEEN NMDA RECEPTOR ANTAGONISTS AND DOPAMINERGIC AGONISTS IN THE 6-HYDROXYDOPAMINE MODEL OF PARKINSON Behavioural Pharmacology. 3: 24. DOI: 10.1097/00008877-199204001-00069 |
0.743 |
|
| 1991 |
Mitchell IJ, Brotchie JM, Brown GD, Crossman AR. Modeling the functional organization of the basal ganglia. A parallel distributed processing approach. Movement Disorders : Official Journal of the Movement Disorder Society. 6: 189-204. PMID 1922123 DOI: 10.1002/mds.870060302 |
0.667 |
|
| 1991 |
Brotchie JM, Crossman AR. D-[3H]aspartate and [14C]GABA uptake in the basal ganglia of rats following lesions in the subthalamic region suggest a role for excitatory amino acid but not GABA-mediated transmission in subthalamic nucleus efferents. Experimental Neurology. 113: 171-81. PMID 1651255 DOI: 10.1016/0014-4886(91)90173-A |
0.69 |
|
| 1991 |
Brotchie JM, Mitchell IJ, Sambrook MA, Crossman AR. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Movement Disorders : Official Journal of the Movement Disorder Society. 6: 133-8. PMID 1647492 DOI: 10.1002/mds.870060208 |
0.737 |
|
| 1990 |
Brotchie JM, Bevan MD, Mitchell IJ, Crossman AR. Anti-parkinsonian effects of EAA antagonists in the entopeduncular nucleus are due to an action at NMDA-like receptors European Journal of Pharmacology. 183: 943-944. DOI: 10.1016/0014-2999(90)92783-F |
0.795 |
|
| 1990 |
Bevan MD, Brotchie JM, Crossman AR. Intracerebral injections of the EAA antagonist kynurenate in the entopeduncular nucleus of the rat elicits a range of hyperkinetic disorders European Journal of Pharmacology. 183: 943. DOI: 10.1016/0014-2999(90)92782-E |
0.772 |
|
| Show low-probability matches. |